Neuron23 Inc.
- Address
- 343 Oyster Point Boulevard Suite 120
Sponsor Overview
Specializations
Parkinson’s disease
Research activity is centered on Parkinson’s disease, with attention to both early Parkinson disease and idiopathic Parkinson disease. The sponsor’s clinical interest extends across Parkinson and parkinsonism-related disease presentations, reflecting a focused neurology portfolio.
- Early Parkinson disease
- Idiopathic Parkinson disease
- Parkinson’s disease
The trial landscape indicates a specific therapeutic emphasis on disease-modifying approaches for movement disorders associated with Parkinsonian syndromes.
Genetically defined neurology
The sponsor’s research includes LRRK2-driven Parkinson’s disease, highlighting an interest in genetically characterized subgroups within neurodegenerative disease. This focus aligns with companion diagnostic-positive populations and biomarker-defined patient selection in neurology.
- LRRK2-driven Parkinson’s disease
- Companion diagnostic-positive
- Biomarker-defined patient groups
Clinical activity in this area points to precision medicine approaches within central nervous system disorders.
Neurodegeneration and central nervous system disease
The funded research sits within the broader field of neurodegenerative disorders, with a particular concentration on central nervous system pathology affecting motor function. The therapeutic interest is aligned with neurological conditions that progress over time and require targeted intervention.
- Neurodegenerative disorders
- Central nervous system disease
- Motor system dysfunction
This area reflects a clinical research focus on neurological disease mechanisms relevant to Parkinsonian syndromes.
Clinical development in neurology
Clinical research activity is organized around a small but concentrated neurology program involving multiple collaborating sites across several countries. The sponsor’s work is directed toward therapeutic development in Parkinson’s disease populations, with an emphasis on identifying and treating patients with defined biological features.
- Neurology
- Parkinson’s disease populations
- Biologically defined subtypes
The research profile is closely tied to clinical investigation in movement disorder medicine.
Sponsored Trials
| Trial Name | Country | Status |
|---|---|---|
| Evaluation of NEU-411 Maleate in LRRK2-Driven Early Parkinson's Disease: A Phase 2 Randomized, Double-Blind, Placebo-Controlled Trial |  Italy Poland Spain | Not Yet Recruiting |
Data & Insights
This sponsor works with 0 molecules, of which 0 are not being studied by other sponsors.
This sponsor has worked with 21 sites across their trial portfolio.
Therapeutic Focus
- 1.Nervous System Diseases1 trial449 other sponsors
Partnered Research Centres
21 centres- Address
- Biocruces Bizkaia Health Research Center Institute, Neurology Sevice- Cruces University Hospital, Edificio Biocruces 1-4a Planta Grupo de Enfermedades Neurodegenerativas, Plaza Cruces s/n, 48903 Barakaldo
- Address
- Via Nicolo' Giustiniani 2, 35128 Padua
- Address
- Piazza Luigi Miraglia 2, 80138 Naples
- Address
- Via Santa Sofia 78, 95123 Catania
- Address
- Ul. Jana Biziela 14, 85-163 Bydgoszcz
- Address
- Largo Francesco Vito 1, 00168 Rome
Want to get in touch with this sponsor?
Send a question and we'll pass it on to Neuron23 Inc..
Need a custom report on this sponsor?
Competitive positioning, market entry, partnership opportunities — tell us the question.
Is something out of date?
Tell us what needs correcting and we'll update this profile.